Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WORTH (which one is right here?): Randomised, crossover study to identify predictive baseline characteristics of response to pioglitazone or vildagliptin as second or third line therapy in patients with Type 2 diabetes

Next Previous
Trial Profile

WORTH (which one is right here?): Randomised, crossover study to identify predictive baseline characteristics of response to pioglitazone or vildagliptin as second or third line therapy in patients with Type 2 diabetes

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2018

At a glance

  • Drugs Pioglitazone (Primary) ; Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms WORTH

    • Most Recent Events

    • 29 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top